Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M. Lamarre D, et al. Among authors: cartier m. Nature. 2003 Nov 13;426(6963):186-9. doi: 10.1038/nature02099. Epub 2003 Oct 26. Nature. 2003. PMID: 14578911 Free article. Clinical Trial.
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.
Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G. Vaillancourt FH, et al. Among authors: cartier m. J Virol. 2012 Nov;86(21):11595-607. doi: 10.1128/JVI.01320-12. Epub 2012 Aug 15. J Virol. 2012. PMID: 22896614 Free PMC article.
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.
Berger KL, Lagacé L, Triki I, Cartier M, Marquis M, Lawetz C, Bethell R, Scherer J, Kukolj G. Berger KL, et al. Among authors: cartier m. Antimicrob Agents Chemother. 2013 Oct;57(10):4928-36. doi: 10.1128/AAC.00822-13. Epub 2013 Jul 22. Antimicrob Agents Chemother. 2013. PMID: 23877706 Free PMC article. Clinical Trial.
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Böcher WO, Datsenko Y, Steinmann G, Scherer J, Stern JO, Kukolj G. Berger KL, et al. Among authors: cartier m. Antimicrob Agents Chemother. 2014;58(2):698-705. doi: 10.1128/AAC.01976-13. Epub 2013 Nov 11. Antimicrob Agents Chemother. 2014. PMID: 24217701 Free PMC article.
Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase.
Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagacé L, Massariol MJ, Dô F, Whitehead P, Lamarre L, Scouten E, Bordeleau J, Landry S, Rancourt J, Fazal G, Simoneau B. Liuzzi M, et al. Among authors: cartier m. J Virol. 2005 Oct;79(20):13105-15. doi: 10.1128/JVI.79.20.13105-13115.2005. J Virol. 2005. PMID: 16189012 Free PMC article.
69 results